Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02460874 : Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Patients with 1-10 newly diagnosed brain metastases deemed to be eligible for

- Subject must have cytologically or histologically confirmed malignancy (this is the
original malignancy, not the brain metastases).

- A diagnostic contrast-enhanced MRI of the brain must be performed within 60 days prior
to registration. The contrast-enhancing intraparenchymal brain tumor must be well
circumscribed and must have a maximum diameter of = 4.0 cm in any direction on the
enhanced scan. If multiple lesions are present and one lesion is at the maximum
diameter, the other(s) must not exceed 3.0 cm in maximum diameter.

- History and physical with neurological examination, height, and weight within 14 days
prior to registration

- No dexamethasone use (or any other corticosteroid use with the purpose of treating
cerebral edema) starting 5 days prior to the treatment planning MRI. Patients may be
tapered to meet this criterion if deemed safe by the treating physician.

- Women of child-bearing potential (e.g. not post-menopausal or permanently sterilized
women) must have a negative pregnancy test obtained within 14 days prior to
registration. This is to prevent potential harm to the fetus by glyburide and

- CBC with differential and CMP including Liver Function Tests (LFTs) obtained within 14
days prior to registration and meeting the following requirements:

- Creatinine Clearance = 50 mL/min.

- Total Bilirubin < 1.5 x the upper limit of normal (ULN).

- ALT and AST = 2.5 x ULN.

- Glucose = 80 mg/dL.

- Hemoglobin = 7 mg/dL.

- Absolute Neutrophil Count > 100 cells/mm3.

- For the Randomized Portion only: Subject must have at least 2 of the following risk
factors: {For the Pilot Portion, it is not required that patients have the risk
factors mentioned in Inclusion Criteria 9.}

- Pretreatment Edema/Tumor ratio (= 35:1) as contoured on a baseline MRI obtained
at most 60 days prior to registration. Patients are allowed to have Whole Brain
Radiotherapy (WBRT) or corticosteroid use between the time of pretreatment MRI
and SRS (as long as the corticosteroids can be safely tapered at least 5 days
prior to the treatment planning MRI and WBRT is at least 4 days prior to

- Greater than 40 pack year history of smoking cigarettes.

- Whole Brain Radiotherapy at least 4 days and no more than 1 year prior to

- RPA Class III.

Exclusion Criteria:

- Known sulfonylurea treatment within 7 days prior to registration. Sulfonylureas
include glyburide/glibenclamide (Diabeta, Glynase); glyburide plus metformin
(Glucovance); glimepiride (Amaryl); repaglinide (Prandin); nateglinide (Starlix);
glipizide (Glucotrol, GlibeneseR, MinodiabR); gliclazide (DiamicronR); tolbutamide
(Orinase, Tolinase); and glibornuride (Glutril).

- Leptomeningeal metastases.

- Known allergy to sulfa or specific allergy to sulfonylurea drugs.

- Use of VEGF inhibitors within 10 days prior to registration.

- Patients receiving an investigational drug within 10 days prior to registration

- Allergy to gadolinium.

- Type 1 diabetes mellitus or Type 2 diabetes mellitus actively receiving treatment.

- Cognitive impairment that precludes a patient from acting as his or her own agent to
provide informed consent.

- Concurrent use of Bosentan.

- Any major medical illnesses or psychiatric impairments that in the treating
physician's opinion will prevent administration or completion of protocol therapy (
which may include patients who are elderly, debilitated, or malnourished persons
and/or those with renal, hepatic or adrenal insufficiency).

- Pregnant or breast feeding women due potential damage to the fetus

- Patients treated on any other therapeutic clinical protocols within 10 days prior to
registration or during participation in the study.

- Inability to undergo MRI or SRS (e.g. due to safety reasons such as presence of a

- Deemed by the treating physician to be unable to eat regular meals.

- Patients currently on beta blockers.

- Patients with a known diagnosis of ongoing alcoholism/alcohol abuse.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557